CAR, as a potential STAT3 blocker, has been reported to inhibit STATS phosphorylation, nuclear translocation, and DNA binding and to bind directly to the Src Homology 2 (SH2) domain of STAT3 and effectively inhibit its dimerization, significantly mitigating the growth and survival of prostate cancer cells and glioblastoma stem cells 16,22. This evidence concerns the gene STAT3 and prostate cancer.